Invention Grant
- Patent Title: Genetic markers indicative of a cancer patient response to trastuzumab (herceptin)
-
Application No.: US13491359Application Date: 2012-06-07
-
Publication No.: US09677139B2Publication Date: 2017-06-13
- Inventor: James Hicks , Alexander Krasnitz
- Applicant: James Hicks , Alexander Krasnitz
- Applicant Address: US NY Cold Spring Harbor
- Assignee: COLD SPRING HARBOR LABORATORY
- Current Assignee: COLD SPRING HARBOR LABORATORY
- Current Assignee Address: US NY Cold Spring Harbor
- Agency: Cooper & Dunham LLP
- Agent Gary J. Gershik
- Main IPC: C12Q1/68
- IPC: C12Q1/68 ; A61K39/395 ; A61K31/337 ; A61K39/00
Abstract:
The invention relates to the fields of therapeutics and identifying candidates for therapy, in particular to a method of identifying candidates for trastuzumab (Herceptin®) therapy in a patient presenting with breast cancer based on the presence or absence of specific genetic markers in a tumor sample from said patient.
Public/Granted literature
- US20160340735A9 GENETIC MARKERS INDICATIVE OF A CANCER PATIENT RESPONSE TO TRASTUZUMAB (HERCEPTIN) Public/Granted day:2016-11-24
Information query
